Key Points
- Immuneering CEO Benjamin Zeskind bought 2,400 shares at $4.56 each, a $10,944 transaction that lifted his ownership by 0.10% to about 2.32 million shares.
- The stock rose 1.3% and opened at $4.60, while remaining below both its 50-day and 200-day moving averages; it has traded between $2.87 and $10.08 over the past year.
- Immuneering recently beat quarterly EPS expectations with a loss of $0.21 per share versus the expected $0.30 loss, and analysts currently rate the stock Moderate Buy with an average price target of $16.50.
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin Zeskind bought 2,400 shares of the firm's stock in a transaction on Tuesday, June 23rd. The stock was purchased at an average cost of $4.56 per share, for a total transaction of $10,944.00. Following the completion of the acquisition, the chief executive officer owned 2,315,252 shares in the company, valued at approximately $10,557,549.12. This trade represents a 0.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Immuneering Trading Up 1.3%
Shares of NASDAQ:IMRX opened at $4.60 on Thursday. The firm has a 50 day moving average of $4.99 and a 200-day moving average of $5.26. The stock has a market capitalization of $297.62 million, a PE ratio of -3.93 and a beta of 0.38. Immuneering Corporation has a 12 month low of $2.87 and a 12 month high of $10.08.
Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.09. On average, research analysts predict that Immuneering Corporation will post -1.12 EPS for the current fiscal year.
Institutional Trading of Immuneering
A number of hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of Immuneering in the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd bought a new position in Immuneering in the 4th quarter valued at approximately $33,000. Levin Capital Strategies L.P. acquired a new stake in Immuneering during the 1st quarter worth approximately $53,000. Cetera Investment Advisers bought a new stake in Immuneering during the 1st quarter worth approximately $67,000. Finally, SummitTX Capital L.P. bought a new stake in Immuneering during the 4th quarter worth approximately $69,000. 67.65% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have weighed in on IMRX. Chardan Capital reaffirmed a "buy" rating and issued a $20.00 target price on shares of Immuneering in a report on Tuesday, May 19th. Oppenheimer reissued an "outperform" rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen downgraded Immuneering from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.50.
Read Our Latest Stock Analysis on IMRX
About Immuneering
(
Get Free Report)
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
